Pathology: mHCC - 1st line (L1);
mHCC - 1st line (L1) | |||||||||
IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | CheckMate 459, 2019 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | ||
durvalumab plus bevacizumab | 1 | T1 | |||||||
Tislelizumab | 1 | T1 | |||||||
atezolizumab plus cabozantinib | 1 | T1 | |||||||
camrelizumab based treatment | 1 | T1 | |||||||
pembrolizumab plus lenvatinib | 1 | T1 | |||||||
sintilimab | 1 | T1 | |||||||
atezolizumab plus bevacizumab | 1 | T1 | |||||||
nivolumab alone | 1 | T1 | |||||||
placebo | 0 | T0 | |||||||
lenvatinib | 0 | T0 | |||||||
sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 |